C-reactive protein and albumin kinetics after antibiotic therapy in community-acquired bloodstream infection

Int J Infect Dis. 2020 Jun:95:50-58. doi: 10.1016/j.ijid.2020.03.063. Epub 2020 Apr 3.

Abstract

Objectives: We assessed C-reactive protein (CRP) and plasma albumin (PA) kinetics to evaluate community-acquired bloodstream infection (CA-BSI) patients' 1-year outcomes.

Methods: Population-based study, with CRP and PA measurements on day 1 (D1) and D4. Relative CRP variations in relation to D1 CRP value were evaluated (CRP-ratio). Patients were classified as fast response, slow response, non-response, and biphasic response.

Results: A total of 935 patients were included. At D4, the CRP-ratio was lower in survivors on D365 in comparison with D4-D30 non-survivors and D30-D365 non-survivors (p<0.001). In comparison with fast response patients, non-response and biphasic response patients had 2.74 and 5.29 increased risk, respectively, of death in D4-D30 and 2.77 and 3.16 increased risk, respectively, of death in D31-D365. PA levels remained roughly unchanged from D1-D4, but lower D1 PA predicted higher short and long-term mortality (p<0.001). The discriminative performance of the CRP-ratio and D1 PA to identify patients with poor short and long-term mortality after adjustments was acceptable (AUROC=0.79).

Conclusions: Serial CRP measurements at D1 and D4 after CA-BSI is clinically useful to identify patients with poor outcome. Individual patterns of CRP-ratio response with PA at D1 further refine our ability of predicting short or long-term mortality.

Keywords: Albumin; C-reactive protein; Community-acquired bloodstream infections; Mortality; Prognosis.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use
  • Bacteremia / blood
  • Bacteremia / drug therapy
  • Bacteremia / mortality*
  • Biomarkers / blood
  • C-Reactive Protein / analysis*
  • Community-Acquired Infections / blood
  • Community-Acquired Infections / drug therapy
  • Community-Acquired Infections / mortality*
  • Female
  • Humans
  • Kinetics
  • Male
  • Middle Aged
  • Serum Albumin / analysis*
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Biomarkers
  • Serum Albumin
  • C-Reactive Protein